About: Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19)

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19) Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 May 2020

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) article scientifique publié en 2020 (fr) scientific article published on 01 May 2020 (en) artículu científicu espublizáu en mayu de 2020 (ast) im Mai 2020 veröffentlichter wissenschaftlicher Artikel (de) наукова стаття, опублікована 1 травня 2020 (uk)
publication date	wds:Q94478889-094F1616-1319-4E27-96CF-4CCF65579296
publication date	2020-05-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q94478889-5FE6A4C1-A112-4EAF-A64F-291C0BF0563E
language of work or name	English
cites work	wds:Q94478889-067553E8-58FC-459B-80CD-1FAC0810F291 wds:Q94478889-0B6EEC06-E1E4-40DD-B925-32BA524E31A3 wds:Q94478889-1912CC56-3621-48EF-B8DD-BE812665DBC9 wds:Q94478889-3D9E5F6C-2E78-4688-A2D8-8D172347685D wds:Q94478889-55381180-75AB-40A4-A92E-F0F6D98A886F wds:Q94478889-57D31DF0-1497-4BFB-9CCC-5C801ADA5A42 wds:Q94478889-8AF86262-B8E5-4FE8-9F16-BBEA2F2B8084 wds:Q94478889-BD69B91B-2456-4B5B-B97F-A0AD46BA279B wds:Q94478889-DACB500B-148D-41C9-AD8D-FE59FA08D387
cites work	Azithromycin and the risk of cardiovascular death Development and validation of a risk score to predict QT interval prolongation in hospitalized patients Hydroxychloroquine and azithromycin as a treatment of COVID‐19: results of an open‐label non‐randomized clinical trial No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the Combination of Hydroxychloroquine and Azithromycin in Patients with Severe COVID-19 Infection Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro [Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia] Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial Considerations for Drug Interactions on QTc in Exploratory COVID-19 (Coronavirus Disease 2019) Treatment
author name string	wds:Q94478889-050A6903-C3A4-497F-BB14-6EA6DBFEB902 wds:Q94478889-0A34478D-91C9-420B-9C4B-766B8D60AF1A wds:Q94478889-0E851B89-4F38-437D-8F67-3355F3DE4A47 wds:Q94478889-2E7BB424-5600-4A30-8DAE-EDEDF9874D3C wds:Q94478889-563A0FF7-32BD-4871-86F7-91910FF43942 wds:Q94478889-5854E325-EB7A-40AC-8A33-6BC79FFF04A2 wds:Q94478889-75E362A1-302A-4325-9913-35AEFD8FD5A6
author name string	Peter J Zimetbaum Howard S Gold Nicholas J Mercuro Christina F Yen David J Shim Christopher M McCoy Timothy R Maher
rdfs:label	Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19) (en) Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19) (nl)
skos:prefLabel	Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19) (en) Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19) (nl)
name	Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19) (en) Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19) (nl)
title	wds:Q94478889-2E7656EC-F278-4690-875A-BA7AE640CD99
title	Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19) (en)
instance of	wds:Q94478889-00A7E738-78E3-4526-B3D1-EFDF1E3884B4
instance of	scholarly article
main subject	wds:Q94478889-24D48787-3CF0-4441-85E5-826645F8E82D wds:Q94478889-4403F793-F8D8-4E82-9C7D-10BF86482E78 wds:Q94478889-586791DE-CDEE-4541-AFB2-31EFB3380722 wds:Q94478889-D7273D60-9DD8-4BEA-9DC2-3EC80CCC60F9
main subject	Coronaviridae wd:Q165399 hydroxychloroquine COVID-19 mortality
PubMed ID	wds:Q94478889-6208CB92-B8D3-40AC-8F8D-73ACD2BE9300
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/32936252
PubMed ID	32936252
published in	wds:Q94478889-16930FDA-158F-43A9-9C0F-17DF7ED30A45
published in	JAMA cardiology
DOI	wds:Q94478889-3DB6EB1E-63C8-4F56-9C67-AA62C3323605
DOI	http://dx.doi.org/10.1001/JAMACARDIO.2020.1834
DOI	10.1001/JAMACARDIO.2020.1834
Dimensions Publication ID	wds:Q94478889-A0091110-6932-4C11-8D16-5B028BBE9C5A
Dimensions Publication ID	1127260213
PMCID	wds:Q94478889-77BF4C93-3A40-4BF3-A274-73070F6BD69F
PMCID	7195692
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q94478889
is cites work of	Sex differences underlying preexisting cardiovascular disease and cardiovascular injury in COVID-19 RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis Management of Heart Failure Patients with COVID-19. A Joint Position Paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives COVID-19 and diabetes mellitus: from pathophysiology to clinical management Absence of relevant QT interval prolongation in not critically ill COVID-19 patients Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial Revisiting the cardiovascular risk of hydroxychloroquine in RA On-target versus off-target effects of drugs inhibiting the replication of SARS-CoV-2 Adverse effects of hydroxychloroquine and azithromycin on contractility and arrhythmogenicity revealed by human engineered cardiac tissues Pathophysiology and pharmacological management of pulmonary and cardiovascular features of COVID-19 QT interval prolongation under hydroxychloroquine/ azithromycin association for inpatients with SARS-CoV-2 lower respiratory tract infection Covid-19 and the cardiovascular system: a comprehensive review Pharmacological and cardiovascular perspectives on the treatment of COVID-19 with chloroquine derivatives COVID-19 and antimicrobial stewardship: What is the interplay? Antiviral mechanisms of candidate chemical medicines and traditional Chinese medicines for SARS-CoV-2 infection
is cites work of	wds:Q98658030-D1BC7F57-DC2F-401C-96CB-62E70D2F19E3 wds:Q97636279-3F9F7F9C-62F8-40E7-BA92-50C79A58692A wds:Q104134952-706F9DB6-F0E8-4EE1-815B-DB86406A6A65 wds:Q102059170-BF5E609C-7FD1-448F-89AF-777C535697EC wds:Q95940808-5A394BF4-A948-4B33-8A46-D0C7071DC58F wds:Q99631317-95C4600D-D231-4ECE-B0E7-51D16601A6F6 wds:Q100395540-A23BCB01-2B10-4AE0-94F5-2D26C0133118 wds:Q104611685-C2992CD2-AC3B-4D4E-8321-AF7EE698400E wds:Q104611687-5A7D9F34-D549-4EAE-9DF1-90BCBB7CFA83

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 183 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software